Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | Data in Brief |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340920314384 |
| _version_ | 1818594549548711936 |
|---|---|
| author | Martin Faehling Christian Schumann Petros Christopoulos Petra Hoffknecht Jürgen Alt Marlitt Horn Stephan Eisenmann Anke Schlenska-Lange Philipp Schütt Felix Steger Wolfgang M. Brückl Daniel C. Christoph |
| author_facet | Martin Faehling Christian Schumann Petros Christopoulos Petra Hoffknecht Jürgen Alt Marlitt Horn Stephan Eisenmann Anke Schlenska-Lange Philipp Schütt Felix Steger Wolfgang M. Brückl Daniel C. Christoph |
| author_sort | Martin Faehling |
| collection | DOAJ |
| description | Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety.211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information on PD-L1 status was obtained for 111 patients. Baseline data include age, gender, ECOG, stage (IASLC 8th ed.), and smoking history. Treatment data include mode of chemoradiotherapy, used chemotherapy agent, and duration of durvalumab therapy. Adverse evants were documented according to CTAEC 5.0. Data were analysed for progression-free survival (PFS), overall survival (OS), and adverse events (AE). The results were published in Lung Cancer [1]. |
| first_indexed | 2024-12-16T11:01:53Z |
| format | Article |
| id | doaj.art-05cec1d0dcbe40d8bb40153fc5d15af0 |
| institution | Directory Open Access Journal |
| issn | 2352-3409 |
| language | English |
| last_indexed | 2024-12-16T11:01:53Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Data in Brief |
| spelling | doaj.art-05cec1d0dcbe40d8bb40153fc5d15af02022-12-21T22:33:59ZengElsevierData in Brief2352-34092021-02-0134106556Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAPMartin Faehling0Christian Schumann1Petros Christopoulos2Petra Hoffknecht3Jürgen Alt4Marlitt Horn5Stephan Eisenmann6Anke Schlenska-Lange7Philipp Schütt8Felix Steger9Wolfgang M. Brückl10Daniel C. Christoph11Klinik für Kardiologie und Pneumologie, Klinikum Esslingen, 73730 Esslingen, Germany; Corresponding author.Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Klinikum Kempten, 87439 Kempten, GermanyThoraxklinik-Heidelberg, 69126 Heidelberg, GermanyKlinik für Thoraxonkologie und Palliativstation, Franziskus-Hospital Harderberg, 49124 Georgsmarienhütte, GermanyIII. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, 55131 Mainz, GermanyLungenClinic Grosshansdorf, Großhansdorf, GermanyUniversitätsklinik und Poliklinik für Innere Medizin I (Gastroenterologie & Pneumologie), Universitätsklinikum Halle (Saale), 06120 Halle, GermanyKlinik für Onkologie und Hämatologie, Krankenhaus Barmherzige Brüder Regensburg, 93049 Regensburg, GermanyOnkologische Gemeinschaftspraxis, Gütersloh, GermanyKlinik und Poliklinik für Strahlentherapie, Universitätsklinikum Regensburg, 93053 Regensburg, GermanyKlinik für Innere Medizin 3, Klinikum Nürnberg Nord, 90419 Nürnberg, GermanyKlinik für Internistische Onkologie und Hämatologie mit integrierter Palliativmedizin, Evang. Kliniken Essen-Mitte, 45136 Essen, GermanyFollowing the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety.211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information on PD-L1 status was obtained for 111 patients. Baseline data include age, gender, ECOG, stage (IASLC 8th ed.), and smoking history. Treatment data include mode of chemoradiotherapy, used chemotherapy agent, and duration of durvalumab therapy. Adverse evants were documented according to CTAEC 5.0. Data were analysed for progression-free survival (PFS), overall survival (OS), and adverse events (AE). The results were published in Lung Cancer [1].http://www.sciencedirect.com/science/article/pii/S2352340920314384NSCLCPD-L1Checkpoint inhibitorSurvivalReal worldOligometastatic |
| spellingShingle | Martin Faehling Christian Schumann Petros Christopoulos Petra Hoffknecht Jürgen Alt Marlitt Horn Stephan Eisenmann Anke Schlenska-Lange Philipp Schütt Felix Steger Wolfgang M. Brückl Daniel C. Christoph Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP Data in Brief NSCLC PD-L1 Checkpoint inhibitor Survival Real world Oligometastatic |
| title | Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP |
| title_full | Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP |
| title_fullStr | Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP |
| title_full_unstemmed | Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP |
| title_short | Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP |
| title_sort | durvalumab after definitive chemoradiotherapy in locally advanced nsclc data of the german eap |
| topic | NSCLC PD-L1 Checkpoint inhibitor Survival Real world Oligometastatic |
| url | http://www.sciencedirect.com/science/article/pii/S2352340920314384 |
| work_keys_str_mv | AT martinfaehling durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT christianschumann durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT petroschristopoulos durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT petrahoffknecht durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT jurgenalt durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT marlitthorn durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT stephaneisenmann durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT ankeschlenskalange durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT philippschutt durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT felixsteger durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT wolfgangmbruckl durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap AT danielcchristoph durvalumabafterdefinitivechemoradiotherapyinlocallyadvancednsclcdataofthegermaneap |